Jinsong Liu, M.D., Ph.D.
1983, Shanghai Medical University
1991, Case Western Reserve University
M. D. Anderson Cancer Center
Pathology
|
Jinsong Liu, M.D., Ph.D. 1983, Shanghai Medical University M. D. Anderson Cancer Center |
Research Interests: Genetic modelling of human ovarian cancer; Senescent stroma in ovarian cancer development; Diagnostic and prognostic markers in ovarian cancer
The research in my laboratory is directed at understanding of genetic events transforming normal human ovarian epithelial cells into ovarian cancer. A strong focus in my laboratory is to introduce oncogenes into human ovarian epithelial cells in a stepwise manner and create genetically defined models for human ovarian cancer in mice. Second area of interest is to study the mechanisms how senescent fibroblasts promote tumor growth. We have shown that fibroblasts near cancer epithelial cells are senescent, such senescent fibroblasts can promote the ovarian tumor growth. Activated RAS oncogene sends chemokine Gro-1 to the stroma to induce accelerated senescence of these fibroblasts thus to synchronize the growth of epithelial cancer cells with their microenvironment. Third major interest is to identify the novel diagnostic and prognostic markers for human ovarian cancer. We are using cDNA microarray to examine the genetic events involved in the transformation from in vitro model and ovarian cancer specimens from ovarian cancer patients. The diagnostic and prognostic markers are compared with ovarian cancer tissue microarray containing hundreds of patients ovarian cancer linked with patients clinical outcome data on a single slide. In this way, we hope to identify early diagnostic markers for ovarian cancer, which can be cured if detected at an early age.
Depending on the student's interests, a tutorial in my laboratory would provide experience with basic cancer mechanism involved in ovarian and breast cancer development or clinical translational research. Our group has been highly productive (see our publication list) and environment for student's learning is superb.
____________
Zhou C, Smith JL, and Liu J (2003) Role of BRCA1 in cellular resistance to palitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 22:2396-404.
Yang G, Thompson JA, Fang B, and Liu J (2003) Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumor growth in a model of human ovarian cancer. Oncogene 22:5694-701.
Yang G, Cai KQ, Thompson-Lanza JA, Bast RC, Jr, and Liu J (2004) Inhibition of breast and ovarian tumor growth through multiple signaling pathways using retrovirus-mediated siRNA silencing against Her-2/neu gene expression. J Biol Chem 279(6):4339-45.
Liu J#, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, and Bast RC, Jr (2004) A genetically defined model for human ovarian cancer. Cancer Res 64:1655-63(# corresponding author).
Young TW, Mei F, Yang G, Thompson JA, Liu J #, and Cheng X # (2004) Activation of anti-oxidant pathways in RAS-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res 64:4577-84 (# co-corresponding author).
Rosen DG, Yang G, Cai KQ, Bast RC, Jr., Gershenson DM, Silva EG, and Liu J (2005) Subcellular localization of p27 kip predicts poor prognosis in human ovarian cancer. Clin Cancer Res 15:11(2 Pt 1):632-7.
Lee P, Rosen DG, Zhu CC, Silva EG, and Liu J (2005) Progesterone receptor expression as an independent prognostic marker in ovarian cancer revealed by tissue microarray. Gynecol Oncol 96(3):671-7-1026
Cheng W, Liu J, Yoshida H,Rosen DG, and Naora H (2005) Morphogenesis of epithelial ovarian cancer is controlled by HOX genes that specify regional identity in the female reproductive tract. Nat Med 11(5):531-537, 2005
Young T, Mei F, Liu J, Bast RC Jr, Kurosky A, and Cheng X (2005) Probing H-Ras-mediated oncogenic transformation by functional proteomics in a genetically defined human ovarian cancer model. Oncogene 24:6174-84.
Rosen DG, Yang G, Bast RC, and Liu J (2006) Use of Ras-transformed human ovarian surface epithelial cells as a model for ovarian cancer. Der C. Ed. Methods in Enzymology 407:660-676.
Trachootham D, Zhou Y, Zhang Hui, Demizu Y, Chen C, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P (2006) Selective killing of oncogenic-transformed cells through ROS-mediated mechanism by â-phenylethyl isothiocyanate. Cancer Cell, 10(3):243-251.
Yang G, Rosen DG, Zhang Z, Bast RC, Jr., Mills GB, Mercado-Uribe I, Liu J (2006) The growth regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci USA 103(44):16472-7.
Rosen DG, Mercado-Uribe I, Yang G, Bast RC, Amin H, Lai R, Liu J (2006) Role of constitutively active Stat3 in ovarian tumorigenesis and prognosis. Cancer 107(11):2730-40.
Rosen DG, Yang G, Deavers MT, and Malpica A, Kavanagh JJ, Mills GB, Liu J (2006) Cyclin E overexpression is an independent prognostic marker for human ovarian cancer. Cancer 106(9):1925-32.
Yang G, Rosen DG, Colacino J, Mercado-Uribe I, Liu J. Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase leads to immortalization of human ovarian surface epithelial cells. Oncogene, Sept 4, 2006, epub ahead of print.
Yang G, Rosen DG, Colacino J, Mercado-Uribe I, Mills GB, Bast RC Jr, Zhou C, Liu J. Knockdown of p53 combined expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells.Carcinogenesis. 2007 Jan; 28(1): 174-82. Epub 2006 July 8.